{"id":545152,"date":"2010-04-27T14:22:52","date_gmt":"2010-04-27T18:22:52","guid":{"rendered":"tag:www.hepatitis-central.com,2010:\/mt\/\/1.817"},"modified":"2010-04-27T14:25:30","modified_gmt":"2010-04-27T18:25:30","slug":"experimental-drug-drops-hep-c-viral-load-by-nearly-100","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/545152","title":{"rendered":"Experimental Drug Drops Hep C Viral Load by Nearly 100%"},"content":{"rendered":"<p>Early results from a Phase II study demonstrate that Bristol-Myers Squibb&#8217;s experimental drug has unrivaled potency against the Hepatitis C virus.<\/p>\n<p>Bristol compound potent against hepatitis C<\/p>\n<p>(Reuters) &#8211; An experimental Bristol-Myers Squibb compound called BMS-790052 is proving to be the most potent yet at treating hepatitis C, an infection poorly treated with existing drugs, company researchers said on Wednesday.<\/p>\n<p>An early, phase I safety study of the compound found it was highly effective at blocking the protein NS5A, a new target that might provide one more weapon against a virus that can quickly develop resistance.<\/p>\n<p>Continue reading this entire article:<br \/>\n<a href=\"http:\/\/www.reuters.com\/article\/idUSTRE63K5QB20100421\">http:\/\/www.reuters.com\/article\/idUSTRE63K5QB20100421<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Early results from a Phase II study demonstrate that Bristol-Myers Squibb&#8217;s experimental drug has unrivaled potency against the Hepatitis C virus. Bristol compound potent against hepatitis C (Reuters) &#8211; An experimental Bristol-Myers Squibb compound called BMS-790052 is proving to be the most potent yet at treating hepatitis C, an infection poorly treated with existing drugs, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-545152","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/545152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=545152"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/545152\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=545152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=545152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=545152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}